[go: up one dir, main page]

MX2018001596A - Anticuerpos anti-receptor ccr7 humanizados. - Google Patents

Anticuerpos anti-receptor ccr7 humanizados.

Info

Publication number
MX2018001596A
MX2018001596A MX2018001596A MX2018001596A MX2018001596A MX 2018001596 A MX2018001596 A MX 2018001596A MX 2018001596 A MX2018001596 A MX 2018001596A MX 2018001596 A MX2018001596 A MX 2018001596A MX 2018001596 A MX2018001596 A MX 2018001596A
Authority
MX
Mexico
Prior art keywords
antibodies
ccr7
conditions
humanized
compositions
Prior art date
Application number
MX2018001596A
Other languages
English (en)
Other versions
MX394165B (es
Inventor
Willem Back Jaap
Cornelis Puijk Wouter
TURKSTRA Johan
Boshuizen Ronald
Original Assignee
Pepmab B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepmab B V filed Critical Pepmab B V
Publication of MX2018001596A publication Critical patent/MX2018001596A/es
Publication of MX394165B publication Critical patent/MX394165B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente descripción proporciona anticuerpos CCR7 anti-humanos humanizados y composiciones que comprenden estos anticuerpos. Los anticuerpos y composiciones son útiles en el tratamiento de un cáncer del cual las células tumorales se expresan un receptor CCR7, en el tratamiento de afecciones inflamatorias, afecciones o complicaciones que surgen de trasplantes de tejidos u órganos, y afecciones o complicaciones que surgen de o se asocian con fibrosis. Los resultados experimentales se detallan para algunos anticuerpos, derivados de anticuerpos de ratón. El anticuerpo de ratón con el nombre interno mab729 [que tiene como CDRs VH1:GLTFRDFA; VH2:ISSGGFYT, VII3:VRRAYRYDGTGDTSALDY, VL1:QDIGPS, VL2;ATS; VL3:LQFASSPLT] se humaniza adicionalmente (nombre interno mAB 650_H1L1). El anticuerpo inhibe la internalización del receptor CCR7, como se muestra por los resultados experimentales.
MX2018001596A 2015-08-10 2016-08-10 Anticuerpos anti-receptor ccr7 humanizados. MX394165B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15180415 2015-08-10
PCT/EP2016/069055 WO2017025569A1 (en) 2015-08-10 2016-08-10 Humanized anti-ccr7 receptor antibodies

Publications (2)

Publication Number Publication Date
MX2018001596A true MX2018001596A (es) 2018-05-02
MX394165B MX394165B (es) 2025-03-24

Family

ID=53836447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001596A MX394165B (es) 2015-08-10 2016-08-10 Anticuerpos anti-receptor ccr7 humanizados.

Country Status (17)

Country Link
US (4) US10640565B2 (es)
EP (1) EP3334457B1 (es)
JP (1) JP6844864B2 (es)
KR (1) KR102663440B1 (es)
CN (1) CN109069620B (es)
AU (1) AU2016305283B2 (es)
BR (1) BR112018002877A2 (es)
CA (1) CA2994214C (es)
DK (1) DK3334457T3 (es)
EA (1) EA037397B1 (es)
ES (1) ES2828368T3 (es)
HU (1) HUE051920T2 (es)
IL (1) IL257359B (es)
MX (1) MX394165B (es)
PT (1) PT3334457T (es)
SI (1) SI3334457T1 (es)
WO (1) WO2017025569A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE051920T2 (hu) * 2015-08-10 2021-03-29 Pepmab B V Humanizált, CCR7 receptor elleni antitestek
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
US20220064311A1 (en) * 2018-12-18 2022-03-03 Catapult Therapeutics B.V. The use of anti-CCR7 mabs for the prevention or treatment of graft-versus-host disease (GvHD)
US12331133B2 (en) * 2019-04-04 2025-06-17 Vanderbilt University Therapeutic antibodies for treating lung cancer
CA3152173A1 (en) * 2019-10-09 2021-04-15 Catapult Therapeutics B.V. Use of an anti-ccr7 antibody in combination therapies with a btk inhibitor and/or bcl2- inhibitor for treating hematological malignancies
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CN112957472B (zh) * 2021-02-05 2021-11-16 无锡市第五人民医院 靶向ccl19/ccr7的乙型肝炎免疫治疗剂及其用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
KR102748862B1 (ko) * 2022-05-19 2025-01-02 국민대학교 산학협력단 Ccr7의 활성 조절 항체
CN116284419B (zh) * 2023-02-07 2024-10-11 深圳市先康达生命科学有限公司 靶向人gucy2c蛋白的单克隆抗体及其应用
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
AU2024247601A1 (en) 2023-03-28 2025-10-23 Nb Health Laboratory Co., Ltd. Antibody, nucleic acid, cell and drug
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用
CN119236085A (zh) * 2024-12-05 2025-01-03 北京大学第三医院（北京大学第三临床医学院） 可治疗系统性硬化病的趋化因子配体19抑制剂的应用
CN120241998B (zh) * 2025-04-02 2025-10-28 广东优赛生物医药科技有限公司 一种药物组合物及其在调降血糖血脂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO2007003216A1 (en) 2005-07-06 2007-01-11 Universidad Autónoma de Madrid Anti-ccr7 receptor antibodies for the treatment of cancer
EP2285403A2 (en) 2008-05-14 2011-02-23 Msm Protein Technologies, Inc. Human monoclonal antibodies against human chemokine receptor ccr7
US8865170B2 (en) 2010-09-28 2014-10-21 Sekisui Chemical Co., Ltd. Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
US20150344580A1 (en) * 2012-06-05 2015-12-03 Eldar Kim Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7
AU2014236867A1 (en) * 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
HUE051920T2 (hu) * 2015-08-10 2021-03-29 Pepmab B V Humanizált, CCR7 receptor elleni antitestek

Also Published As

Publication number Publication date
US12122838B2 (en) 2024-10-22
EP3334457A1 (en) 2018-06-20
CN109069620B (zh) 2022-04-26
JP2018522568A (ja) 2018-08-16
AU2016305283A1 (en) 2018-02-22
SI3334457T1 (sl) 2021-01-29
US20220135693A1 (en) 2022-05-05
CA2994214A1 (en) 2017-02-16
IL257359A (en) 2018-04-30
KR20180030931A (ko) 2018-03-26
WO2017025569A1 (en) 2017-02-16
MX394165B (es) 2025-03-24
KR102663440B1 (ko) 2024-05-07
EA037397B1 (ru) 2021-03-24
CN109069620A (zh) 2018-12-21
HUE051920T2 (hu) 2021-03-29
EA201890447A1 (ru) 2018-11-30
BR112018002877A2 (pt) 2018-11-06
US11254749B2 (en) 2022-02-22
AU2016305283B2 (en) 2022-05-26
CA2994214C (en) 2024-03-12
IL257359B (en) 2022-03-01
EP3334457B1 (en) 2020-08-26
US20200362043A1 (en) 2020-11-19
DK3334457T3 (da) 2020-09-21
US20250092147A1 (en) 2025-03-20
ES2828368T3 (es) 2021-05-26
US10640565B2 (en) 2020-05-05
PT3334457T (pt) 2020-09-24
US20180237529A1 (en) 2018-08-23
JP6844864B2 (ja) 2021-03-17

Similar Documents

Publication Publication Date Title
MX2018001596A (es) Anticuerpos anti-receptor ccr7 humanizados.
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
MX2017006323A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
PE20190510A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201990208A1 (ru) Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения
MX2022002682A (es) Anticuerpos anti-cd73.
MX393951B (es) Anticuerpos antisortilina y métodos para su uso.
EA201791270A1 (ru) Модифицированные april-связывающие антитела
MX2017000205A (es) Anticuerpos anti-tau humanizados.
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
UA123202C2 (uk) Антитіло до тау-білка і його застосування
PE20190737A1 (es) Anticuerpos anti-cd27
CO2017011512A2 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
AR119507A1 (es) Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3
MX2025013942A (es) Anticuerpos contra mucina 16 y metodos de uso de los mismos
BR112015023086A2 (pt) anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.